Education
About Us
Working with TipRanks
Follow Us
Edwards Lifesciences (EW)
NYSE:EW
EW Stock Chart & Stats
Day’s Range― - ―
52-Week Range$64.01 - $83.00
Previous CloseN/A
Volume821.68K
Average Volume (3M)4.31M
Market Cap
$45.89B
Enterprise Value$42.68B
Total Cash (Recent Filing)$3.90B
Total Debt (Recent Filing)$699.40M
Price to Earnings (P/E)53.4
Beta0.88
Next Earnings
Oct 22, 2025EPS Estimate
0.59Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.67
Shares Outstanding587,100,000
10 Day Avg. Volume4,374,882
30 Day Avg. Volume4,313,998
Financial Highlights & Ratios
PEG Ratio0.05
Price to Book (P/B)4.43
Price to Sales (P/S)8.13
P/FCF Ratio152.63
Enterprise Value/Market Cap0.93
Enterprise Value/Revenue7.71
Enterprise Value/Gross Profit9.73
Enterprise Value/Ebitda24.09
Forecast
1Y Price Target
$89.05Price Target Upside13.93% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering26
Bulls Say, Bears Say
Bulls Say
EarningsManagement raised full-year EPS guidance to the high end of $2.45-$2.55, indicating a positive adjustment in financial expectations.
Financial PerformanceEdwards Lifesciences management raised the 2025 adjusted EPS guidance to account for the removal of expected dilution from the JenaValve deal.
Sales GrowthEW reported WW TAVR sales grew +8.9% y/y to $1.13bn (+3% vs. consensus $1.10bn).
Bears Say
Growth ProspectsThe potential failure of the JenaValve deal is seen as a negative for future growth, as it would eliminate the addition of a self-expanding valve option for aortic regurgitation patients.
Market CompetitionThe near-term outlook is clouded by TAVR growth decelerating and price competition in Europe.
Regulatory RisksThe FTC's lawsuit to block the JenaValve deal introduces a risk that the deal may not close, removing a potential future growth opportunity for Edwards Lifesciences.
Edwards Lifesciences News
EW FAQ
What was Edwards Lifesciences’s price range in the past 12 months?
Edwards Lifesciences lowest stock price was $64.00 and its highest was $83.00 in the past 12 months.
What is Edwards Lifesciences’s market cap?
Edwards Lifesciences’s market cap is $45.89B.
When is Edwards Lifesciences’s upcoming earnings report date?
Edwards Lifesciences’s upcoming earnings report date is Oct 22, 2025 which is in 70 days.
How were Edwards Lifesciences’s earnings last quarter?
Edwards Lifesciences released its earnings results on Jul 24, 2025. The company reported $0.67 earnings per share for the quarter, beating the consensus estimate of $0.624 by $0.046.
Is Edwards Lifesciences overvalued?
According to Wall Street analysts Edwards Lifesciences’s price is currently Undervalued.
Does Edwards Lifesciences pay dividends?
Edwards Lifesciences does not currently pay dividends.
What is Edwards Lifesciences’s EPS estimate?
Edwards Lifesciences’s EPS estimate is 0.59.
How many shares outstanding does Edwards Lifesciences have?
Edwards Lifesciences has 587,100,000 shares outstanding.
What happened to Edwards Lifesciences’s price movement after its last earnings report?
Edwards Lifesciences reported an EPS of $0.67 in its last earnings report, beating expectations of $0.624. Following the earnings report the stock price went up 5.541%.
Which hedge fund is a major shareholder of Edwards Lifesciences?
Currently, no hedge funds are holding shares in EW
Edwards Lifesciences Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$89.05 (13.93% Upside)
$89.05 (13.93% Upside)
Blogger Sentiment
Bullish
EW Sentiment 83%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Increased
By 848.4K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $439.5K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.3%
Last 30 Days ▼ 5.3%
Last 30 Days ▼ 5.3%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
20.91%
12-Months-Change
Fundamentals
Return on Equity
15.71%
Trailing 12-Months
Asset Growth
33.56%
Trailing 12-Months
Company Description
Edwards Lifesciences
Edwards Lifesciences Corporation is a global leader in heart valve replacement and repair therapies, as well as hemodynamic monitoring. The company specializes in innovative medical devices and technologies that address the needs of patients with structural heart disease and critical care monitoring. Edwards Lifesciences operates primarily in two sectors: surgical heart valves and transcatheter heart valves, delivering advanced solutions that provide improved outcomes for patients with cardiovascular conditions. Core products include the SAPIEN valve system for transcatheter aortic valve replacement and a range of monitoring solutions for critically ill patients.
EW Earnings Call
Q2 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call for Edwards Lifesciences was largely positive, with the company reporting strong double-digit sales growth and raising its full-year guidance. The Transcatheter Aortic Valve Replacement (TAVR) and Transcatheter Mitral and Tricuspid Therapies (TMTT) segments showed significant growth, and the company saw strong international performance. However, there were some concerns about decreased gross profit margins and the anticipated negative impact on earnings per share from the JenaValve acquisition.View all EW earnings summariesEW Net sales Breakdown
75.49% Transcatheter Aortic Valve Replacement
18.04% Surgical Structural Heart
6.47% Transcatheter Mitral and Tricuspid Therapies
EW Stock 12 Month Forecast
Average Price Target
$89.05
▲(13.93% Upside)
Technical Analysis
Ownership Overview
0.23% Insiders
22.22% Mutual Funds
1.07% Other Institutional Investors
51.65% Public Companies and
Individual Investors